Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Hydroxylated Long-Chain Acylcarnitines are Biomarkers of Mitochondrial Myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early life exposures to perfluoroalkyl substances in relation to adipokine hormone levels at birth and during childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hippocampal volume, cognitive functions, depression, anxiety, and quality of life in patients with Cushing's syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Coronary plaque composition assessed by cardiac computed tomography using adaptive Hounsfield unit thresholds

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intrapancreatic accessory spleen mimicking malignant tumor: three case reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CONTEXT: Most Turner syndrome (TS) girls need exogenous estrogen treatment to induce puberty and normal uterine growth. After puberty the optimal estrogen treatment protocol has not been determined.

OBJECTIVE: To compare two doses of oral 17ß-estradiol on uterine size.

DESIGN: A double-blind 5 years randomized controlled clinical trial.

SETTING: Ambulatory care.

PARTICIPANTS: 20 young TS women (19.2±2.5 years, range 16.0-24.9) participated. 16 patients completed the study. No patients withdrew due to adverse effects.

INTERVENTION: The lower-dose (LD) group took 2 mg 17ß-estradiol/day orally and placebo. The higher-dose (HD) group took 4 mg 17ß-estradiol/day orally.

RESULTS: Uterine size increased significantly more in the HD group compared to the LD group (P=0.038), with a gain in uterine volume within the first three years of treatment of 19.6 ml (95% CI = [4.0; 19.0]) in the HD group compared to 11.5 ml (95% CI = [11.2; 27.9]) in the LD group. The difference in three-year gain was 8.1 ml (95% CI = [0.7; 15.9]). At the last visit there were no significant differences in uterine volume between the groups.

CONCLUSION: High dose oral 17ß-estradiol induces a steeper increase in uterine volume within the first years of treatment compared to the lower dose. However, the uterine growth potential seems to be the same in most young TS women making the duration of treatment equally significant as estrogen dose, although a few TS did not experience sufficient uterine growth on 2 mg of estradiol.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
ISSN0021-972X
DOI
StatusE-pub ahead of print - 15 okt. 2019

Bibliografisk note

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 58139124